Anti-LAG-3 antibody LBL-007 in combination with anti-PD-1 antibody toripalimab, in patients with advanced malignant tumors: A phase Ib/II, open-label, multicenter, dose escalation/expansion study

被引：0
|
作者：
Yang, Yunpeng
Zhao, Yuanyuan
Fang, Wenfeng
Huang, Yan
Zhang, Yaxiong
Ba, Yi
Wang, Zhen
Deng, Chao
Hu, Desheng
Wang, Wei
Li, Guiling
Luo, Suxia
Fu, Zhichao
Zhu, Haisheng
Wang, Huili
Zhao, Shiwei
Li, Tao
Cai, Charles
Zhang, Li
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2024-CT227
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT227
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Anti-LAG-3 antibody LBL-007 plus anti-PD-1 antibody toripalimab in advanced nasopharyngeal carcinoma and other solid tumors: an open-label, multicenter, phase Ib/II trial
    Chen, Gang
    Sun, Dong-Chen
    Ba, Yi
    Zhang, Ya-Xiong
    Zhou, Ting
    Zhao, Yuan-Yuan
    Zhao, Hong-Yun
    Fang, Wen-Feng
    Huang, Yan
    Wang, Zhen
    Deng, Chao
    Hu, De-Sheng
    Wang, Wei
    Lin, Jin-Guan
    Li, Gui-Ling
    Luo, Su-Xia
    Fu, Zhi-Chao
    Zhu, Hai-Sheng
    Wang, Hui-Li
    Cai, Sheng-Li
    Kang, Xiao-Qiang
    Zhang, Li
    Yang, Yun-Peng
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2025, 18 (01)
  • [2] Anti-LAG-3 antibody LBL-007 in combination with anti-PD-1 antibody tislelizumab with or without chemotherapy in patients with advanced nasopharyngeal cancer and other malignant tumors: A phase Ib/II dose escalation/expansion study
    Yang, Yunpeng
    Chen, Yu
    Qu, Song
    Liu, Lei
    Chen, Lisha
    Yang, Kunyu
    Huang, Xiaoming
    Li, Jingao
    Wang, Rensheng
    Zhu, Haisheng
    Zhao, Shiwei
    Li, Tao
    Cai, Shengli
    Zhang, Li
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [3] Anti-LAG-3 antibody LBL-007 in combination with toripalimab in patients with unresectable or metastatic melanoma: A phase., open-label, multicenter, dose escalation/expansion study.
    Bai, Xue
    Li, Mei
    Pu, Xingxiang
    Cheng, Ying
    Chen, Jing
    Jiang, Yu
    Chen, Xue
    Liu, Jingjing
    Fan, Li
    Guo, Jun
    Si, Lu
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [4] Updated safety and efficacy results from the phase I study of either LBL-007 (an anti-LAG-3 antibody) in combination with toripalimab (an anti-PD-1 antibody) or LBL-007 in combination with toripalimab and axitinib in patients with advanced melanoma
    Bai, Xue
    Li, Mei
    Chen, Yu
    Si, Lu
    Chen, Jing
    Pu, Xingxiang
    Cheng, Ying
    Zou, Zhengyun
    Zhao, Shiwei
    Li, Tao
    Cai, Shengli
    Guo, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [5] A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies
    Lin, Chia-Chi
    Garralda, Elena
    Schoeffski, Patrick
    Hong, David S.
    Siu, Lillian L.
    Martin, Miguel
    Maur, Michela
    Hui, Rina
    Soo, Ross A.
    Chiu, Joanne
    Zhang, Tian
    Ma, Brigette
    Kyi, Chrisann
    Tan, Daniel S. W.
    Cassier, Philippe A.
    Sarantopoulos, John
    Weickhardt, Andrew
    Carvajal, Richard D.
    Spratlin, Jennifer
    Esaki, Taito
    Rolland, Frederic
    Akerley, Wallace
    Deschler-Baier, Barbara
    Rispoli, Lawrence
    Samant, Tanay S.
    Chowdhury, Niladri Roy
    Gusenleitner, Daniel
    Kwak, Eunice L.
    Askoxylakis, Vasileios
    De Braud, Filippo
    ONCOIMMUNOLOGY, 2024, 13 (01):
  • [6] A phase I open-label, dose escalation of YH003, an anti-CD40 monoclonal antibody, in combination with toripalimab (anti-PD-1 mAb) in patients with advanced solid tumors
    Coward, Jermaine
    Ben Markman
    Nagrial, Adnan
    Abed, Afaf
    Walpole, Imogen
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [7] CITRINO: phase 1 dose escalation study of anti-LAG-3 antibody encelimab alone or in combination with anti-PD-1 dostarlimab in patients with advanced/metastatic solid tumours
    J. Randolph Hecht
    Jean-Marie Michot
    David Bajor
    Amita Patnaik
    Ki Y. Chung
    Judy Wang
    Gerald Falchook
    James M. Cleary
    Richard Kim
    Anuradha Krishnamurthy
    Omkar Marathe
    Hagop Youssoufian
    Catherine Ellis
    Angela Waszak
    Srimoyee Ghosh
    Hailei Zhang
    Kaitlin Yablonski
    Shruti D. Shah
    Ivan Diaz-Padilla
    Susanna Ulahannan
    BJC Reports, 3 (1):
  • [8] A phase Ia/Ib, dose-escalation/expansion study of BI 907828, an MDM2-p53 antagonist, in combination with BI 754091, an anti-PD-1 antibody, and BI 754111, an anti-LAG-3 antibody, in patients with advanced solid tumors
    Tolcher, Anthony
    Hafez, Navid
    Yamamoto, Noboru
    Park, Jaehong
    Grempler, Rolf
    Lucarelli, Anthony
    Vallaster, Markus P.
    Wang, Bushi
    Hyman, David
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [9] Phase I open-label, dose escalation of YH003, an anti-CD40 monoclonal antibody in combination with toripalimab (anti-PD-1 mAb) in patients with advanced solid tumors.
    Coward, Jermaine
    Abed, Afaf
    Nagrial, Adnan
    Markman, Ben
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [10] Anti-PD-1/TGF-βRII bispecific antibody fusion protein LBL-015 in patients with advanced malignant tumors: A phase I, first-in-human, open-label, multicenter, dose-escalation study
    Li, Qun
    Zhao, Wei
    Wang, Wei
    Chen, Po
    Niu, Zuoxing
    Ni, Shuqin
    Luo, Suxia
    Qiao, Junjing
    Wang, Mingxi
    Li, Yong
    He, Yan
    Liu, Tao
    Li, Tao
    Cai, Shengli
    Li, Jin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345